XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53

The XPO1 inhibitor selinexor was recently approved in relapsed/refractory DLBCL patients but only demonstrated modest anti-DLBCL efficacy, prompting us to investigate the prognostic effect of XPO1 in DLBCL patients and the rational combination therapies in high-risk DLBCL. High XPO1 expression (XPO1...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Manman, Zhang, Mingzhi, Xu-Monette, Zijun Y., Pham, Lan V., Tzankov, Alexandar, Visco, Carlo, Fang, Xiaosheng, Bhagat, Govind, Zhu, Feng, Dybkaer, Karen, Chiu, April, Tam, Wayne, Zu, Youli, Hsi, Eric D., Choi, William W. L., Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés J. M., Møller, Michael B., Parsons, Benjamin M., van Krieken, J. Han, Piris, Miguel A., Winter, Jane N., Hagemeister, Fredrick, Alinari, Lapo, Li, Yong, Andreeff, Michael, Xu, Bing, Young, Ken H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641823/
https://www.ncbi.nlm.nih.gov/pubmed/33148342
http://dx.doi.org/10.1186/s13045-020-00982-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641823/
https://www.ncbi.nlm.nih.gov/pubmed/33148342
http://dx.doi.org/10.1186/s13045-020-00982-3

Ejemplares similares